(PHR) Phreesia - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 688m USD | Total Return: -66.3% in 12m

Stock Software, Payments, Scheduling, Registration, Revenue Cycle
Total Rating 26
Safety 28
Buy Signal -1.60
Health Information Services +7.4
Health Care Technology -2.2
Market Cap: 688m
Avg Trading Vol: 17.5M USD
ATR: 5.53%
Peers RS (IBD): 9.4
Risk 5d forecast
Volatility49.1%
Rel. Tail Risk-7.34%
Reward TTM
Sharpe Ratio-1.86
Alpha-95.92
Character TTM
Beta1.691
Beta Downside2.279
Drawdowns 3y
Max DD75.72%
CAGR/Max DD-0.47
EPS (Earnings per Share) EPS (Earnings per Share) of PHR over the last years for every Quarter: "2021-04": -0.11, "2021-07": -0.33, "2021-10": -0.46, "2022-01": -0.7, "2022-04": -0.71, "2022-07": -0.61, "2022-10": -0.48, "2023-01": -0.43, "2023-04": -0.38, "2023-07": -0.34, "2023-10": -0.25, "2024-01": -0.21, "2024-04": -0.35, "2024-07": -0.31, "2024-10": 0.0367, "2025-01": 0.1848, "2025-04": 0.2259, "2025-07": 0.01, "2025-10": 0.07, "2026-01": 0.4404,
EPS CAGR: 160.79%
EPS Trend: 92.9%
Last SUE: 1.82
Qual. Beats: 1
Revenue Revenue of PHR over the last years for every Quarter: 2021-04: 48.291, 2021-07: 51.007, 2021-10: 55.915, 2022-01: 58.02, 2022-04: 63.354, 2022-07: 67.867, 2022-10: 73.103, 2023-01: 76.586, 2023-04: 83.845, 2023-07: 85.83, 2023-10: 91.619, 2024-01: 95.005, 2024-04: 101.217, 2024-07: 102.115, 2024-10: 106.8, 2025-01: 109.681, 2025-04: 115.936, 2025-07: 117.255, 2025-10: 120.333, 2026-01: 127.067,
Rev. CAGR: 20.39%
Rev. Trend: 98.5%
Last SUE: 0.19
Qual. Beats: 0
Risks
Technicals: volatile
Description: PHR Phreesia

Phreesia Inc. (PHR) operates a SaaS platform for the healthcare sector in the US and Canada. The company integrates software and payment processing, a common model in healthcare technology to streamline administrative tasks.

Its offerings include appointment scheduling, patient registration, and revenue cycle management, which encompasses insurance verification and payment collection. These services address critical operational needs for healthcare providers.

Phreesia deploys its platform across various modalities: mobile devices, dedicated tablets, web-based dashboards, and on-site kiosks. This multi-channel approach caters to diverse user preferences within healthcare settings.

The company serves a broad client base, from individual practices to large health systems, and also works with pharmaceutical, medical device, and biotechnology firms. This diversified client portfolio is typical for healthcare technology providers seeking broad market penetration. ValueRay offers further data-driven insights on companies like Phreesia.

Headlines to Watch Out For
  • Healthcare provider adoption of SaaS platform drives recurring revenue
  • Payment processing volume directly impacts revenue growth
  • Regulatory changes in healthcare IT could increase compliance costs
  • Competition from established EHR vendors pressures market share
Piotroski VR‑10 (Strict) 5.5
Net Income: -20.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 6.60 > 1.0
NWC/Revenue: 20.10% < 20% (prev 21.26%; Δ -1.16% < -1%)
CFO/TA 0.12 > 3% & CFO 78.8m > Net Income -20.2m
Net Debt (19.4m) to EBITDA (32.7m): 0.59 < 3
Current Ratio: 1.53 > 1.5 & < 3
Outstanding Shares: last quarter (61.5m) vs 12m ago 5.52% < -2%
Gross Margin: 85.15% > 18% (prev 0.68%; Δ 8.45k% > 0.5%)
Asset Turnover: 91.35% > 50% (prev 108.1%; Δ -16.73% > 0%)
Interest Coverage Ratio: -1.44 > 6 (EBITDA TTM 32.7m / Interest Expense TTM 7.11m)
Altman Z'' -5.67
A: 0.15 (Total Current Assets 279.8m - Total Current Liabilities 183.2m) / Total Assets 663.8m
B: -1.20 (Retained Earnings -799.2m / Total Assets 663.8m)
C: -0.02 (EBIT TTM -10.2m / Avg Total Assets 526.1m)
D: -2.45 (Book Value of Equity -799.0m / Total Liabilities 326.6m)
Altman-Z'' Score: -5.67 = D
Beneish M -2.93
DSRI: 1.17 (Receivables 98.3m/73.6m, Revenue 480.6m/419.8m)
GMI: 0.80 (GM 85.15% / 67.86%)
AQI: 1.32 (AQ_t 0.54 / AQ_t-1 0.41)
SGI: 1.14 (Revenue 480.6m / 419.8m)
TATA: -0.15 (NI -20.2m - CFO 78.8m) / TA 663.8m)
Beneish M-Score: -2.93 (Cap -4..+1) = A
What is the price of PHR shares? As of April 04, 2026, the stock is trading at USD 8.38 with a total of 15,699,580 shares traded.
Over the past week, the price has changed by -23.77%, over one month by -32.34%, over three months by -51.11% and over the past year by -66.30%.
Is PHR a buy, sell or hold? Phreesia has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy PHR.
  • StrongBuy: 10
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the PHR price?
Wallstreet Target Price 27.6 229.7%
Analysts Target Price 27.6 229.7%
PHR Fundamental Data Overview as of 01 April 2026
P/E Forward = 13.3333
P/S = 1.485
P/B = 2.2321
Revenue TTM = 480.6m USD
EBIT TTM = -10.2m USD
EBITDA TTM = 32.7m USD
Long Term Debt = 3.35m USD (from longTermDebt, two quarters ago)
Short Term Debt = 6.20m USD (from shortLongTermDebt, two quarters ago)
Debt = 93.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.4m USD (from netDebt column, last quarter)
Enterprise Value = 707.3m USD (687.9m + Debt 93.2m - CCE 73.8m)
Interest Coverage Ratio = -1.44 (Ebit TTM -10.2m / Interest Expense TTM 7.11m)
EV/FCF = 11.08x (Enterprise Value 707.3m / FCF TTM 63.8m)
FCF Yield = 9.02% (FCF TTM 63.8m / Enterprise Value 707.3m)
FCF Margin = 13.28% (FCF TTM 63.8m / Revenue TTM 480.6m)
Net Margin = -4.20% (Net Income TTM -20.2m / Revenue TTM 480.6m)
Gross Margin = 85.15% ((Revenue TTM 480.6m - Cost of Revenue TTM 71.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev 68.40%)
Tobins Q-Ratio = 1.07 (Enterprise Value 707.3m / Total Assets 663.8m)
Interest Expense / Debt = 5.86% (Interest Expense 5.46m / Debt 93.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -8.08m (EBIT -10.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.53 (Total Current Assets 279.8m / Total Current Liabilities 183.2m)
Debt / Equity = 0.28 (Debt 93.2m / totalStockholderEquity, last quarter 337.2m)
Debt / EBITDA = 0.59 (Net Debt 19.4m / EBITDA 32.7m)
Debt / FCF = 0.30 (Net Debt 19.4m / FCF TTM 63.8m)
Total Stockholder Equity = 309.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.84% (Net Income -20.2m / Total Assets 663.8m)
RoE = -6.52% (Net Income TTM -20.2m / Total Stockholder Equity 309.4m)
RoCE = -3.27% (EBIT -10.2m / Capital Employed (Equity 309.4m + L.T.Debt 3.35m))
 RoIC = -2.59% (negative operating profit) (NOPAT -8.08m / Invested Capital 312.1m)
 WACC = 11.06% (E(687.9m)/V(781.1m) * Re(11.93%) + D(93.2m)/V(781.1m) * Rd(5.86%) * (1-Tc(0.21)))
Discount Rate = 11.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.06%
[DCF] Terminal Value 58.19% ; FCFF base≈43.0m ; Y1≈28.2m ; Y5≈12.9m
[DCF] Fair Price = 2.46 (EV 167.7m - Net Debt 19.4m = Equity 148.3m / Shares 60.3m; r=11.06% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 92.88 | EPS CAGR: 160.8% | SUE: 1.82 | # QB: 1
Revenue Correlation: 98.45 | Revenue CAGR: 20.39% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-07-31): EPS=0.36 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=-1 | Analysts=7
EPS current Year (2027-01-31): EPS=1.51 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+0 | Growth EPS=+16.5% | Growth Revenue=+14.9%
EPS next Year (2028-01-31): EPS=1.78 | Chg7d=+0.010 | Chg30d=+0.010 | Revisions Net=-2 | Growth EPS=+18.4% | Growth Revenue=+9.1%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle